What is BioMarin Pharmaceutical Inventory-to-Revenue?
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. BioMarin Pharmaceutical's Average Total Inventories for the quarter that ended in Mar. 2025 was $1,254 Mil. BioMarin Pharmaceutical's Revenue for the
three
months ended in Mar. 2025 was $745 Mil.
BioMarin Pharmaceutical's Inventory-to-Revenue for the quarter that ended in Mar. 2025 was 1.68.
BioMarin Pharmaceutical's Inventory-to-Revenue for the quarter that ended in Mar. 2025
increased
from Dec. 2024 (1.61) to Dec. 2024 (1.68)
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
BioMarin Pharmaceutical's Days Inventory for the
three
months ended in Mar. 2025 was 754.86.
Inventory Turnover measures how fast the company turns over its inventory within a year.
BioMarin Pharmaceutical's Inventory Turnover for the quarter that ended in Mar. 2025 was 0.12.
BioMarin Pharmaceutical Inventory-to-Revenue Historical Data
The historical data trend for BioMarin Pharmaceutical's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioMarin Pharmaceutical's Inventory-to-Revenue
For the Biotechnology subindustry, BioMarin Pharmaceutical's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMarin Pharmaceutical's Inventory-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where BioMarin Pharmaceutical's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioMarin Pharmaceutical's Inventory-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.
Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.
More Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
BioMarin Pharmaceutical's Days Inventory for the
three
months ended in Mar. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioMarin Pharmaceutical Inventory-to-Revenue Related Terms
Thank you for viewing the detailed overview of BioMarin Pharmaceutical's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BMRN has been successfully added to your 